Mifepristone is under clinical development by Corcept Therapeutics and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mifepristone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mifepristone (Korlym) is a synthetic steroid with anti-progestational effects, acts as a contraceptive agent. It is formulated as tablets for oral route of administration. Korlym is indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Mifepristone is under development for the treatment of metastatic non-small cell lung cancer, metastatic castration-resistant prostate cancer, ovarian cancer, major depressive disorder and alcohol use disorder. It is also under development for the treatment of triple negative breast cancer in combination with nab-paclitaxel and HER2 negative breast cancer in combination with pembrolizumab.
It was also under development for the treatment of central serous chorioretinopathy, psychotic major depression, Alzheimer's disease, endogenous Cushing’s syndrome and antipsychotic-induced weight gain.
Corcept Therapeutics overview
Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome. Corcept’s major pipeline products include relacorilant for endogenous Cushing syndrome; miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for the treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis, alcohol use disorder and post-traumatic stress disorder among others. Corcept is headquartered in Menlo Park, California, the US.
For a complete picture of Mifepristone’s drug-specific PTSR and LoA scores, buy the report here.